
Dr. Jack Regan, CEO LexaGene and BioPub Investment Interview – January 26, 2022
Dr. Jack Regan, CEO and Founder of LexaGene gives an update to BioPub Investment group on January 26, 2021.
Dr. Jack Regan, CEO and Founder of LexaGene gives an update to BioPub Investment group on January 26, 2021.
The global bioburden testing market for bio-pharma contamination is approximately $10B, with over 350M tests run annually. LexaGene provides early detection for mycoplasma, aiding in validating product quality for biopharmaceutical manufacturers.
Single-use manufacturing has provided for a large degree of flexibility in terms of production volumes but have also brought about efficiencies in sterility control by reducing hands on cleaning and sterilization necessary for stainless steel.
On-site qPCR testing lets veterinarians make better treatment decisions faster than waiting on culture and sensitivity testing from a reference laboratory.
Veterinary Antimicrobial Stewardship programs are critical to not only improve patient outcomes, but support global action against antimicrobial resistance.